Lidocaine ophthalmic Pregnancy and Breastfeeding Warnings
Brand names: Akten
Lidocaine ophthalmic Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: B
Animal studies have failed to reveal evidence of fetal harm when given subcutaneously at doses up to 50 mg/kg. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Lidocaine ophthalmic Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Yes
Comments:
-Systemic exposure is not expected.
-The effects in the nursing infant are unknown.
See also
References for pregnancy information
- Product Information. Akten (lidocaine ophthalmic). Akorn Inc. 2008.
References for breastfeeding information
- Product Information. Akten (lidocaine ophthalmic). Akorn Inc. 2008.
- United States National Library of Medicine. Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT 2013.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.